OBJECTIVES: The objectives of this study were to determine (1) the increase in antimicrobial resistance to frequently used antibiotics in the hospital setting over time and (2) the correlation between the amount of use of an antibiotic in a specific medical specialty and the observed resistance to that antibiotic in that specialty. METHOD: The total use of antibiotics and the use of ciprofloxacin (CIP), co-amoxicillin + clavulanic acid (AMCL) and first and second-generation cephalosporins (CEF), respectively, in individual medical specialties were measured between 2001 and 2006 by means of prevalence surveys (two per year). The antimicrobial susceptibility patterns among E. coli isolated from hospitalized patients between 2003 and 2006 were obtained from the Laboratory Information System. Trends over time and correlation between use and resistance were calculated. RESULTS: 6,639 patients were included in the prevalence surveys, of whom 3.0% (195) were treated with CIP, 9.7% (642) with AMCL, and 3.5% (232) with CEF. 4,790 E. coli isolates were obtained from hospitalized patients. Resistance to all antibiotics significantly increased over time, with the regression line showing that the strongest increase in resistance was for CIP (2.6% per year). There were large variations in antimicrobial use between various medical specialties. A significant correlation was found between the ward-specific prevalence of use and the percentage of resistance for CIP (R = 0.81, p < 0.001) and AMCL (R = 0.82, p = 0.003). CONCLUSION: At the level of individual medical specialties within one hospital, a higher prevalence of antimicrobial use among patients was associated with a significantly higher observed antimicrobial resistance. The use of CIP was associated with a stronger increase in resistance than the use of beta-lactams.
OBJECTIVES: The objectives of this study were to determine (1) the increase in antimicrobial resistance to frequently used antibiotics in the hospital setting over time and (2) the correlation between the amount of use of an antibiotic in a specific medical specialty and the observed resistance to that antibiotic in that specialty. METHOD: The total use of antibiotics and the use of ciprofloxacin (CIP), co-amoxicillin + clavulanic acid (AMCL) and first and second-generation cephalosporins (CEF), respectively, in individual medical specialties were measured between 2001 and 2006 by means of prevalence surveys (two per year). The antimicrobial susceptibility patterns among E. coli isolated from hospitalized patients between 2003 and 2006 were obtained from the Laboratory Information System. Trends over time and correlation between use and resistance were calculated. RESULTS: 6,639 patients were included in the prevalence surveys, of whom 3.0% (195) were treated with CIP, 9.7% (642) with AMCL, and 3.5% (232) with CEF. 4,790 E. coli isolates were obtained from hospitalized patients. Resistance to all antibiotics significantly increased over time, with the regression line showing that the strongest increase in resistance was for CIP (2.6% per year). There were large variations in antimicrobial use between various medical specialties. A significant correlation was found between the ward-specific prevalence of use and the percentage of resistance for CIP (R = 0.81, p < 0.001) and AMCL (R = 0.82, p = 0.003). CONCLUSION: At the level of individual medical specialties within one hospital, a higher prevalence of antimicrobial use among patients was associated with a significantly higher observed antimicrobial resistance. The use of CIP was associated with a stronger increase in resistance than the use of beta-lactams.
Authors: W Goettsch; W van Pelt; N Nagelkerke; M G Hendrix; A G Buiting; P L Petit; L J Sabbe; A J van Griethuysen; A J de Neeling Journal: J Antimicrob Chemother Date: 2000-08 Impact factor: 5.790
Authors: J Garau; M Xercavins; M Rodríguez-Carballeira; J R Gómez-Vera; I Coll; D Vidal; T Llovet; A Ruíz-Bremón Journal: Antimicrob Agents Chemother Date: 1999-11 Impact factor: 5.191
Authors: H P Endtz; G J Ruijs; B van Klingeren; W H Jansen; T van der Reyden; R P Mouton Journal: J Antimicrob Chemother Date: 1991-02 Impact factor: 5.790
Authors: Ebbing Lautenbach; Joshua P Metlay; Warren B Bilker; Paul H Edelstein; Neil O Fishman Journal: Clin Infect Dis Date: 2005-08-24 Impact factor: 9.079
Authors: James A Karlowsky; Mark E Jones; Clyde Thornsberry; Ian R Friedland; Daniel F Sahm Journal: Antimicrob Agents Chemother Date: 2003-05 Impact factor: 5.191
Authors: David M Livermore; Dorothy James; Mark Reacher; Catriona Graham; Thomas Nichols; Peter Stephens; Alan P Johnson; Robert C George Journal: Emerg Infect Dis Date: 2002-05 Impact factor: 6.883
Authors: Johan Van Eldere; Robertino M Mera; Linda A Miller; James A Poupard; Heather Amrine-Madsen Journal: Antimicrob Agents Chemother Date: 2007-08-06 Impact factor: 5.191
Authors: Ina Willemsen; Ben Cooper; Carin van Buitenen; Marjolein Winters; Gunnar Andriesse; Jan Kluytmans Journal: Antimicrob Agents Chemother Date: 2010-06-28 Impact factor: 5.191
Authors: Miroslava Htoutou Sedláková; Karel Urbánek; Vladimíra Vojtová; Hana Suchánková; Peter Imwensi; Milan Kolář Journal: BMC Res Notes Date: 2014-07-16
Authors: Walter Zingg; Aliki Metsini; Céline Gardiol; Carlo Balmelli; Michael Behnke; Nicolas Troillet; Andreas Widmer; Didier Pittet Journal: Euro Surveill Date: 2019-08
Authors: Diamantis Plachouras; Tommi Kärki; Sonja Hansen; Susan Hopkins; Outi Lyytikäinen; Maria Luisa Moro; Jacqui Reilly; Peter Zarb; Walter Zingg; Pete Kinross; Klaus Weist; Dominique L Monnet; Carl Suetens Journal: Euro Surveill Date: 2018-11